Hi Gujarat
Menu
  • Home
  • Business
  • Lifestyle
  • Health
  • Education
  • National
  • PR
Menu

Optimus PharmaSeeks Emergency Approval to Conduct Phase 3 Clinical Trial of Molnupiravir for COVID-19 in India

Posted on April 27, 2021 by Hi Gujarat Webdesk

Hyderabad [Telangana], April 27: Dr. D. Srinivas Reddy, Chairman, and CEO of Optimus Pharma announced that they have filed for seeking emergency approval for Phase 3 Clinical Trial from the Drugs Controller General of India. Once the approval is granted for Phase 3 Clinical Trial, we would be extensively accelerating the manufacturing of our in-house developed generic version of Molnupiravir for making it available in the Indian market as soon as possible. Optimus Pharma is committed to halting the pandemic across the nation and ensuring immediate relief to all those who have been infected with the highly virulent SARS-CoV-2.

Optimus Pharma is pleased to announce the development of oral Molnupiravir on the fast lane. Optimus Pharma is becoming a key player in the fight against the COVID-19 pandemic in India has already achieved very high production levels of Favipiravir one of our flagship drugs for COVID-19 infection. In a bid to develop and diversify our anti-viral portfolio especially against SARS-CoV-2, we are here with yet another promising drug to compensate for the lack of antiviral drugs in the market further diversifying our antivirals portfolio. In hindsight of the raging second wave, Molnupiravir has been developed for non-hospitalized mild to moderate infections of SARS-CoV-2. Optimus Pharma is aggressively pushing for achieving scalability for 800mg dose of the drug.

Our available pre-clinical data on Molnupiravir already demonstrated that there were no adverse clinical signs and mortality observed in any of the treatment groups, as compared to the control group of animals with high efficacy and thereby effectively neutralizing virulence of the SARS-CoV-2 virus in the test group as compared to control group.

The drug is effective against a variety of viruses that use an RNA-dependent RNA polymerase (RdRp), as is the case with SARS-CoV-2 which is directly responsible for the transcription of Viral m-RNA of the virus in the infected subject. Early in vitro tests of Molnupiravir on SARS-CoV-2 revealed a steady decrease in virus output that was proportional to the dose of Molnupiravir used. Since the RdRp of SARS-CoV-2 and SARS-CoV, which the drug was designed to treat, has 99.1% nucleotide similarity hence, this was possible. Repeated drug exposure quickly neutralized virus populations, ensuring that none of the random mutations mediate drug resistance. As the drug is introduced in higher amounts, the titer levels and genome output of SARS-CoV-2 decrease exponentially.

It has been observed that Molnupiravir is only marginally successful in preventing extreme SARS-CoV-2 infection that is severe cases of the infection. This might have been the reason for their withdrawal and continue the trial only with non-hospitalized patients that are subjects with mild to moderate infection. We aim to do the same and establish its efficacy in the same treatment group.

Phase 2 Clinical Trial study on enrolled 202 non-hospitalized adults is already made available by the innovator of the molecule. Virological analysis was characterized by a marked decrease in positive viral culture in subjects who received Molnupiravir (all doses) relative to placebo – at day 5: 0% (0/47) for Molnupiravir and 24% (6/25) for placebo. Furthermore, the secondary objective for a faster decrease in infectious virus among people with early COVID-19 who were treated with Molnupiravir is encouraging and Phase 3 Clinical Trials are warranted for checking the efficacy of the molecule across demographics, particularly as the SARS-CoV-2 virus continues to spread and evolve globally.

Unlike the current drugs being administered intravenously, Molnupiravir is administered orally. This makes it a promising drug to halt the disease progression in the early stages as well as mount a powerful response against moderate infection levels. The fact that this molecule can be consumed as an orally administered drug in the form of an 800mg capsule renders a maverick advantage to achieve scalability in terms of upscaling from gm scale to multi-ton levels in a short time frame, thereby ensuring availability in the Indian market at a comparatively exponential scale. In vitro assays indicate that it is significantly more effective than the drugs being used currently, and the safety profile appears to be satisfactory.

13 thoughts on “Optimus PharmaSeeks Emergency Approval to Conduct Phase 3 Clinical Trial of Molnupiravir for COVID-19 in India”

  1. Solar panel says:
    January 13, 2023 at 10:04 pm

    Thank you for great article. I look forward to the continuation. https://yoykem.com.tr/

  2. no 19 butik says:
    January 14, 2023 at 2:18 am

    This post post made me think. I will write something about this on my blog. Have a nice day!! https://no19butik.com/

  3. farmasi üyelik formu says:
    January 14, 2023 at 7:15 am

    Veryy rapidly this web site will be famoous among all blog users due to it’s pleasant articles https://farmasiucretsizuyelik.com/

  4. edgense says:
    January 27, 2023 at 9:52 pm

    Chronic oral administration of pimobendan to dogs with echocardiographic and radiographic evidence of cardiomegaly secondary to MMVD, in the absence of concurrent cardiovascular medication, results in the prolongation of the preclinical period, and is safe and well tolerated viagra nitric oxide

  5. Klalaemurnefc says:
    January 30, 2023 at 6:09 pm

    where buy generic lyrica price how to get lyrica without prescription cost of lyrica without a prescription

  6. Slalaemurneao says:
    February 1, 2023 at 12:36 am

    can you get pregabalin price buy generic pregabalin no prescription can you buy cheap pregabalin price

  7. totosite says:
    February 1, 2023 at 2:22 am

    I’ve been troubled for several days with this topic. totosite, But by chance looking at your post solved my problem! I will leave my blog, so when would you like to visit it?

  8. edgense says:
    February 1, 2023 at 9:30 am

    This is treated with an antibiotic called Erythromycin best place to buy generic cialis online Contrary to common misconceptions, exercise is safe after having lymph nodes removed

  9. Slalaemurnesa says:
    February 2, 2023 at 7:49 pm

    order propecia tablets can i get generic propecia buy propecia without prescription

  10. Glalaemurneke says:
    February 4, 2023 at 6:01 pm

    predinson prescriptions buy prednisone without a prescription prednisone buy

  11. edgense says:
    February 6, 2023 at 2:57 am

    Nolvadex works by competitively binding to target estrogen sites like those at the breast can you buy priligy viagra quitting finasteride hairlosstalk Obama and his aides have been trying to navigate a tricky path on Egypt, expressing displeasure with the army s actions while not entirely breaking a relationship crucial to U

  12. Jmitmb says:
    February 6, 2023 at 5:36 pm

    buy arimidex 1mg online buy anastrozole 1 mg online anastrozole 1 mg oral

  13. Slalaemurneos says:
    February 6, 2023 at 7:33 pm

    furosemide dogs bumetanide vs lasix how long does furosemide take to work

Leave a Reply Cancel reply

Your email address will not be published.

Recent Posts

  • H.E. Sheikh N M Al Nahayan presents Golden Excellence award to Satish Sanpal
  • Mr. Ajay Kakar: The man spearheading Parasoft to new heights
  • Let’s Wash Hands with HELLO KITTY!!
  • Sachamoti Royalratan Sabudana’s new ad campaign launched
  • Shankaraa Foundation presents ‘Soma – The Festival For The Arts’

Recent Comments

  • GOXENAXIA on Sindhu Trade Links Board Approves Bonus Issue
  • WillieCog on Sindhu Trade Links Board Approves Bonus Issue
  • Jamesruinc on Coirfit Mattress in a Bag- Made for Bigger Dreams!
  • WillieCog on GJ TECH Enabling players–platform collaboration for global gaming platforms
  • 나나 알바 on Google Rolled out RCS Messaging in India I Here’s Why Brands Need to ADOPT It

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020

Categories

  • A
  • Business
  • Design
  • Education
  • English
  • Entertainment
  • Health
  • Hindi
  • Lifestyle
  • National
  • Press Release
  • Sports
  • Technology
  • Uncategorized
  • World
  • एजुकेशन
  • गुजरात
  • नेशनल
  • बिज़नस
  • लाइफस्टाइल
  • हेल्थ

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
©2023 Hi Gujarat | WordPress Theme by Superbthemes.com